The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.

Related News Articles

Headline
The House today voted 220-207 to pass the Inflation Reduction Act (H.R. 5376), sending it to President Biden for his signature. Passed by the Senate Sunday,…
Headline
The first Centers for Medicare & Medicaid Services model to screen patients for health-related social needs and refer them to needed services ended in…
Headline
The Senate this weekend is expected to take up the Inflation Reduction Act (H.R. 5376), the latest version of the Build Back Better Act, a roughly $700 billion…
Headline
The Department of Justice today filed a lawsuit challenging an Idaho law restricting abortion. The complaint seeks a declaratory judgment that the law…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that updates the inpatient prospective payment system rates by 2.6% in FY 2023…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule for the long-term care hospital prospective payment system for fiscal year 2023,…